Squarepoint Ops LLC Has $8.18 Million Stock Holdings in Janux Therapeutics, Inc. $JANX

Squarepoint Ops LLC trimmed its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 532,321 shares of the company’s stock after selling 71,679 shares during the quarter. Squarepoint Ops LLC’s holdings in Janux Therapeutics were worth $8,176,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Janux Therapeutics in the 4th quarter worth approximately $34,000. Versant Capital Management Inc boosted its stake in Janux Therapeutics by 42.8% in the 2nd quarter. Versant Capital Management Inc now owns 2,615 shares of the company’s stock valued at $40,000 after buying an additional 784 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Janux Therapeutics in the 4th quarter valued at $51,000. Osaic Holdings Inc. grew its position in Janux Therapeutics by 704.6% in the second quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after acquiring an additional 3,037 shares during the period. Finally, Quantbot Technologies LP grew its position in Janux Therapeutics by 2,290.0% in the second quarter. Quantbot Technologies LP now owns 5,497 shares of the company’s stock valued at $84,000 after acquiring an additional 5,267 shares during the period. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $17.68 on Friday. The stock’s fifty day moving average price is $16.91 and its two-hundred day moving average price is $15.22. Janux Therapeutics, Inc. has a 52-week low of $12.12 and a 52-week high of $35.34. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -10.78 and a beta of 2.53.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The business had revenue of $10.27 million during the quarter, compared to analysts’ expectations of $19.07 million. On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JANX. Truist Financial reissued a “buy” rating and set a $26.00 price objective (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. Guggenheim lowered their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a report on Friday, August 7th. TD Cowen upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Stifel Nicolaus set a $35.00 price target on shares of Janux Therapeutics in a report on Friday, August 7th. Finally, Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a research report on Monday, August 24th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $36.46.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.